NMRA · Neumora Therapeutics, Inc.
$1.61
+0.01 (+0.63%)
At close · Jul 17
Market Cap
$298.31M
Shares
185,284,244
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joshua Pinto | President | $6,743,238 |
| Paul L. Berns | CEO | $4,562,461 |
| Bill Aurora | Chief Operating and Development Officer | $3,302,000 |
| Henry Gosebruch | CEO | $1,319,273 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Paul L. Berns | Chairman | $8,648,393 |
| Bill Aurora | Chief Operating and Development Officer | $5,201,926 |
| Henry Gosebruch | CEO | $4,785,930 |
| Joshua Pinto | President | $4,630,573 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Henry Gosebruch | CEO | $21,999,269 |
| Rob Lenz | Head of Research and Development | $13,582,881 |
| Paul L. Berns | Chairman | $8,570,268 |
| Jason Duncan | Chief Legal and Administrative Officer | $4,119,980 |
| Bill Aurora | Chief Operating and Development Officer | $3,179,845 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Paul L. Berns | CEO | $2,634,924 |